Changing therapeutic paradigms in glaucoma management (Q36181220)

12 August 2017

title

Changing therapeutic paradigms in glaucoma management (English)

1 reference

12 August 2017

David R

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 July 1998

1 reference

Expert Opinion on Investigational Drugs

12 August 2017

published in

1 reference

12 August 2017

volume

7

1 reference

12 August 2017

issue

7

1 reference

12 August 2017

page(s)

1063-1086

1 reference

Number of people with glaucoma worldwide

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Total cholesterol and high-density lipoprotein levels as risk factors for increased intraocular pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Neuroprotection of the optic nerve in glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Vascular pathogenesis of normal-tension glaucoma: a possible pathogenetic factor, other than intraocular pressure, of glaucomatous optic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Molecular genetics is revolutionizing our understanding of ophthalmic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Recent advances in molecular genetics of glaucomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Identification of a gene that causes primary open angle glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Genetic heterogeneity of primary open angle glaucoma and ocular hypertension: linkage to GLC1A associated with an increased risk of severe glaucomatous optic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Systemic adverse effects of topical ophthalmic agents. Implications for older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Medical treatment of glaucoma--a reappraisal of the risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

New approaches to antiglaucoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Comparison of the ocular beta-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Systemic side effects of topical beta-adrenergic blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

21 January 2018

Longterm timolol therapy

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Adverse effects experienced by patients taking timolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Adverse reactions from timolol administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Respiratory difficulties with betaxolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Congestive heart failure from betaxolol. Case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Retrobulbar Arterial Hemodynamic Effects of Betaxolol and Timolol in Normal-Tension Glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Effects of dorzolamide hydrochloride 2% on the retinal circulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

The uveoscleral outflow routes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Latanoprost and hyperpigmentation of eyelashes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Adverse side effects associated with latanoprost.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

A comparative study of the effects of timolol and latanoprost on blood flow velocity of the retrobulbar vessels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Effects of apraclonidine on aqueous humor dynamics in human eyes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Apraclonidine and clonidine: a comparison of efficacy and side effects in normal and ocular hypertensive volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

The effects of apraclonidine on conjunctival oxygen tension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Mechanisms of Adrenergic Agonist Induced Allergy Bioactivation and Antigen Formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Eliprodil, a non-competitive, NR2B-selective NMDA antagonist, protects pyramidal neurons in hippocampal slices from hypoxic/ischemic damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

L-deprenyl protects injured retinal precursor cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

The b-wave of the electroretinogram as an index of retinal ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Apoptosis in ocular disease: a molecular overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

Growth factors and gangliosides as neuroprotective agents in excitotoxicity and ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.7.1063

10.1517/13543784.7.7.1063

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference